Tri Nguyen, MD
Ophthalmology · Fountain Valley, CANPI 1669436002
Payments from drug & device makers
Across 350 payments — averaging $38.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$9K
- AbbVie$2K
- Alcon$674
- Novartis$428
- Aerie Pharmaceuticals, Inc.$390
- Bausch & Lomb Americas Inc.$341
- plus $2K from 15 others
What the payments were for
- Speaking & faculty fees$5,00037%
- Travel & lodging$1,1248%
- Food & beverage$7,45355%
- Entertainment$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 104 | $8,500 |
| AbbVie(2 entities) | 84 | $1,526 |
| Alcon | 20 | $674 |
| Novartis | 32 | $428 |
| Aerie Pharmaceuticals, Inc. | 24 | $390 |
| Bausch & Lomb Americas Inc. | 23 | $341 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $306 |
| Oyster Point Pharma, Inc. | 9 | $297 |
| Mallinckrodt Hospital Products Inc. | 12 | $265 |
| Amgen(2 entities) | 6 | $185 |
| Shire North American Group Inc | 8 | $156 |
| Rayner Intraocular Lenses Limited | 3 | $93 |
| Harrow Eye, LLC | 3 | $84 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $74 |
| Glaukos Corporation | 2 | $64 |
| Eyevance Pharmaceuticals LLC | 3 | $63 |
| Kala Pharmaceuticals, Inc. | 2 | $43 |
| Dompe US, Inc. | 2 | $40 |
| Optos, Inc. | 1 | $25 |
| Thea Pharma Inc. | 1 | $25 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$4,624
- BROMSITE$1,603
- TYRVAYA$167
- AcrySof IQ PanOptix UV IOL$144
- LOTEMAX SM$118
- PROLENSA$115
How this compares
$13,602 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 1,021 | $734,592 |
| Cyclosporine | 780 | $469,296 |
| CequaCyclosporine | 564 | $355,932 |
| VyzultaLatanoprostene Bunod | 125 | $51,799 |
| CombiganBrimonidine Tartrate/Timolol | 204 | $46,903 |
| VevyeCyclosporine | 52 | $46,439 |
| XiidraLifitegrast | 36 | $28,650 |
| BromsiteBromfenac Sodium | 109 | $27,605 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 116 | $23,424 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 83 | $17,609 |
| TyrvayaVarenicline Tartrate | 23 | $14,961 |
| RocklatanNetarsudil Mesylat/Latanoprost | 34 | $13,658 |
| EysuvisLoteprednol Etabonate | 26 | $12,925 |
| Lotemax SmLoteprednol Etabonate | 51 | $12,767 |
| ZerviateCetirizine Hcl | 29 | $12,614 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Lumigan | $1,526 | $789,4911,243 claims |
| Sun Pharmaceutical Industries Inc.Cequa, Bromsite | $8,500 | $383,537673 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $341 | $80,448161 claims |
| Harrow Eye, LLCVevye | $84 | $46,43952 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Lotemax, Prolensa, Besivance | $306 | $45,528154 claims |
| AlconSimbrinza, Azopt | $674 | $28,248130 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $390 | $21,70858 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $297 | $14,96123 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $43 | $12,92526 claims |
| Eyevance Pharmaceuticals LLCZerviate | $63 | $12,61429 claims |
| NovartisIlevro | $428 | $5,88016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Fountain Valley
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.